Highly rated in
Highly rated in
Check Dr. Edwin Choy's experience treating your condition:
About Dr. Edwin Choy

Edwin Choy is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Choy has been practicing medicine for over 23 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Liposarcoma, Bone Tumor, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Choy is currently accepting new patients.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 16 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Edwin Choy it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Edwin Choy accepts the following insurance:

  •  Ambetter
  •  Anthem

Call to see if your plan is accepted.
55 Fruit St, Boston, MA 02114
Background & Education
Graduate Institution
New York University School Of Medicine, 2000
Hematology Oncology
Internal Medicine in MA
Hospital Affiliations
Wentworth-Douglass Hospital
Brigham And Womens Hospital
Massachusetts General Hospital
Cooley Dickinson Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma or Rhabdomyosarcoma Following Failure of Prior Chemotherapy
A Phase II Trial of Sitravatinib (MGCD516), a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing Sarcoma
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Phase I Study of Nilotinib Given With Radiation For Patients With High Risk Chordoma
Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy
View 13 Less Clinical Trials -

149 Total Publications

NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors